DOW JONES23,433.57+779.71 3.44%
S&P 5002,749.98+90.57 3.41%
NASDAQ8,090.90+203.64 2.58%

Morgan Stanley Maintains Overweight on Regenxbio, Lowers Price Target to $55

Morgan Stanley maintains Regenxbio (NASDAQ:RGNX) with a Overweight and lowers the price target from $58 to $55.

Benzinga · 03/03/2020 13:17

Morgan Stanley maintains Regenxbio (NASDAQ:RGNX) with a Overweight and lowers the price target from $58 to $55.